Press release - Mindpeak receives 2m€ funding

June 18, 2020
Hamburg start-up Mindpeak receives funding of 2 million Euros. The Hamburg-based start-up Mindpeak has successfully raised grant funding totalling around 2 million euros. The funding comes from the EU Commission's Horizon 2020 program and the Profi Transfer funding pool of the Hamburg Investment and Development Bank.

Hamburg start-up Mindpeak receives funding of 2 million Euros

The Hamburg-based start-up Mindpeak has successfully raised grant funding totalling around 2 million euros. The funding comes from the EU Commission's Horizon 2020 program and the Profi Transfer funding pool of the Hamburg Investment and Development Bank. Via image recognition systems, Mindpeak’s proprietary algorithms help increase the productivity of pathology labs in clinical routine and promise to support pathologists in their work to precisely diagnose cancers based on digital slides. Mindpeak cooperates with renowned research institutions such as the Charité Berlin and laboratories in Hamburg and Cambridge. The company's solution is immediately ready for use in the laboratory setting without the need for any complex pre-adjustment.

"I am very pleased about these funding commitments. They are proof of the innovative power of our research and products and of the strong endorsement by the European Union and the City of Hamburg in our recent traction and goal to deliver fast, reliable and widely accessible cancer diagnostic tools," said Mindpeak's Managing Director Felix Faber. Faber founded the company two years ago with his partner Dr. Tobias Lang. Mindpeak currently employs 25 people and has already launched the first products for the identification and quantification of breast cancer cells.

"The highly selective funding from the EU program Horizon 2020 and Profi Transfer confirm our investment in Mindpeak as a very innovative startup in the area of cancer diagnostics," said Gencer Sahin, Investment Manager at IFB Innovationsstarter GmbH.

Funds from the EU Horizon 2020 EIC (Enhanced European Innovation Council) program are used to support start-ups as well as small and medium-sized companies that develop highly innovative ideas with an exceptionally large market potential. The Profi Transfer program of the Hamburg Investment and Promotion Bank (IFB) supports the transfer of technology and knowledge between companies and universities or research institutions with grants. Mindpeak received IFB's funding to support its close cooperation towards the development of AI-supported cancer diagnostics with the renowned Institute for Haematopathology Hamburg. "The funds will be used on the one hand to further develop and continuously improve our algorithm for the detection of specific cancer types such as breast cancer at present, as well as to extend the application of our machine learning models to new cancer types," explained Faber.

Press Release

Related reading

Press Release
8 min read

Mindpeak Earns IVDR Certification, Reinforcing Its Commitment to Quality and Regulatory Excellence

Certification under the EU's In Vitro Diagnostic Regulation validates Mindpeak's quality management system, confirming it meets the EU's most rigorous standard for cancer-related diagnostic devices -  a milestone for the Hamburg-based AI diagnostics company as it deepens partnerships across Europe.

HAMBURG, Germany – SEPTEMBER 11, 2026 – Mindpeak, a leading developer of AI-powered software for digital pathology, today announced it has achieved certification under the EU In Vitro Diagnostic Medical Devices Regulation (IVDR). The certification, issued following rigorous assessment by BSI, a leading EU Notified Body, confirms that Mindpeak's quality management system meets the EU's most demanding regulatory standard for diagnostic software.

Setting a New Standard for AI-Powered Diagnostics

IVDR is widely regarded as one of the most demanding regulatory frameworks in the medical device world, requiring manufacturers to demonstrate robust, auditable quality processes across the full device lifecycle — from design and development through manufacturing, distribution, and post-market surveillance. Achieving this certification places Mindpeak's organizational infrastructure on the same regulatory footing required of every IVD device placed on the EU market.

"Achieving IVDR certification is a defining milestone for Mindpeak - it's proof that our technology doesn't just perform in the lab, it meets the same standard that governs every diagnostic device used in patient care across Europe. This is the foundation we'll build the next phase of our platform on." said Felix Faber, CEO and Founder of Mindpeak.

Built for Scale, Built for Trust

Mindpeak's certified quality management system meets the requirements of ISO 13485 and IVDR Annex IX, as confirmed by BSI Group - a reflection of the standards Mindpeak holds itself to as it builds AI diagnostics for high-stakes clinical use. This milestone reflects the maturity of Mindpeak's regulatory infrastructure as it continues to expand its footprint with laboratories and diagnostic partners across Europe.

By meeting IVDR requirements, Mindpeak reinforces its commitment to delivering AI-powered pathology tools that pathologists and laboratories can trust for high-stakes clinical decision-making - further solidifying the company's position at the forefront of AI-driven precision diagnostics.

About Mindpeak

Mindpeak is the leading company in AI-powered digital pathology, bridging the gap from biomarker development to clinical diagnostics. Founded in 2018, Mindpeak's AI technology enables laboratories to extract actionable insights from IHC, H&E, and mIF tissue images - ranging from subcellular biomarker quantification to predictive patient stratification. The solutions support both routine diagnostics as well as the discovery and translation of novel biomarkers into real-world clinical applications.

Press Release
8 min read

Mindpeak joins CellCarta's Digital Pathology & AI Consortium

CellCarta has launched the Digital Pathology & AI Consortium, bringing together leading companies at the intersection of AI and pathology to advance drug development. Mindpeak is proud to be among the founding members.

The consortium is built on a core premise: AI in pathology only delivers value when it is embedded in strong laboratory infrastructure, clinical workflows, and deep pathology expertise. By combining these capabilities across member organizations, the group aims to generate robust, reproducible insights that support precision medicine at scale.

We are pleased to announce that Mindpeak will be exhibiting at AACR 2026 in collaboration with Revolune. At this year’s meeting, we will present a joint approach to simplifying spatial biology workflows by combining Revolune’s multiplex immunofluorescence (mIF) reagents with Mindpeak’s AI-powered image analysis - PhenoScout.
Press Release
8 min read

Mindpeak at AACR 2026 - Together with Revolune

We are pleased to announce that Mindpeak will be exhibiting at AACR 2026 in collaboration with Revolune. At this year’s meeting, we will present a joint approach to simplifying spatial biology workflows by combining Revolune’s multiplex immunofluorescence (mIF) reagents with Mindpeak’s AI-powered image analysis - PhenoScout.

We are pleased to announce that Mindpeak will be exhibiting at AACR 2026 in collaboration with Revolune.

At this year’s meeting, we will present a joint approach to simplifying spatial biology workflows by combining Revolune’s multiplex immunofluorescence (mIF) reagents with Mindpeak’s AI-powered image analysis - PhenoScout.

By integrating staining and analysis into a streamlined workflow, researchers can generate high-quality multiplex tissue data and efficiently derive meaningful biological insights. This supports key applications such as biomarker discovery and translational cancer research.

We believe that reducing complexity is essential to accelerating the adoption of spatial biology technologies. Together with Revolune, our goal is to make advanced multiplex workflows more accessible, scalable, and practical for real-world use.

For more details, please read the full press release:
https://lnkd.in/dSRZaEAw

If you are attending AACR 2026, we invite you to visit us at booth #1660

Ready to advance your diagnostics

Connect with our team to explore how precision pathology works in your setting